Genmab

Ultime notizie

Titoli nella lingua originale della fonte.

• 
  Major Shareholder Announcement (si apre in una nuova scheda)

  GlobeNewswire · 2 ott 2026

• 
  Genmab Eyes Three Pivotal Phase III Cancer Readouts in Q4 (si apre in una nuova scheda)

  27 set 2026

• Grant of Restricted Stock Units and Warrants to Employees in Genmab (si apre in una nuova scheda)

  24 set 2026

• 
  Genmab (CPSE:GMAB) Stock Sees Modest Fair Value Cut As Analysts Weigh Pipeline Risks (si apre in una nuova scheda)

  24 set 2026

• Notice to Convene an Extraordinary General Meeting of Genmab A/S (si apre in una nuova scheda)

  8 set 2026

• Could Genmab (GMAB) Stock Win as Royalty Growth Fuels a New Earnings Cycle? (si apre in una nuova scheda)

  26 ago 2026

• Genmab to Participate in Upcoming Investor Conferences (si apre in una nuova scheda)

  25 ago 2026

• Could AbbVie Inc. (ABBV) Win as Genmab A/S (GMAB) Faces a New Regulatory Test for Epcoritamab? (si apre in una nuova scheda)

  13 ago 2026

• Here Are Wednesday’s Top Wall Street Analyst Research Calls: The Gap, Genmab, Hilton Worldwide, Intuitive Surgical, Marriott International, Merck, Novo Nordisk, Okta, and More (si apre in una nuova scheda)

  12 ago 2026

• Genmab Stock Rises 4.4% as Drug Royalties Lift Outlook (si apre in una nuova scheda)

  7 ago 2026

• Genmab (GMAB) Q2 2026 Earnings Call Transcript (si apre in una nuova scheda)

  7 ago 2026

• Genmab AS (GMAB) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth and Strategic ... (si apre in una nuova scheda)

  6 ago 2026

• Genmab A/S Q2 Earnings Call Highlights (si apre in una nuova scheda)

  6 ago 2026

• Genmab shares jump 8% after upbeat results prompt 2026 outlook raise (si apre in una nuova scheda)

  6 ago 2026

• Genmab Announces Financial Results for the First Half of 2026 (si apre in una nuova scheda)

  6 ago 2026

• Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight (si apre in una nuova scheda)

  13 lug 2026

• 
  Is Genmab A/S (GMAB) Stock Undervalued After Positive Epkinly DLBCL Trial Results? (si apre in una nuova scheda)

  Insider Monkey · 8 lug 2026

• 
  Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma (si apre in una nuova scheda)

  GlobeNewswire · 6 lug 2026

• 
  Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival (si apre in una nuova scheda)

  Business Wire · 29 giu 2026

• 
  Capital Increase in Genmab as a Result of Employee Warrant Exercise (si apre in una nuova scheda)

  GlobeNewswire · 16 giu 2026

• 
  Genmab’s EPCORE Data Deepens Lymphoma Profile As Investors Weigh Upside (si apre in una nuova scheda)

  Simply Wall St. · 15 giu 2026

• 
  Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) (si apre in una nuova scheda)

  GlobeNewswire · 13 giu 2026

• 
  Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients (si apre in una nuova scheda)

  Business Wire · 11 giu 2026

• 
  Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients (si apre in una nuova scheda)

  GlobeNewswire · 11 giu 2026